St. Louis Children’s Hospital

Transplant Protocols

• 01-0923 A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Non- Myloablative Preparatory Regime with Campath-1H, Fludarabine and Melphalan
• CTN 0501 Double vs. Single Umbilical Cord Blood Transplants
• CTN 0601 Unrelated Donor Hematopoietic Cell Transplantation for Children with Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen
• AAML0531 A Phase III Randomized Trial of Gemtuzumab Ozogamicin Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescences, and Young Adults
• AAML05P1 Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (HCT) for Refractory and Relapsed Acute Myelogenous Leukemia (AML) and Newly Diagnosed AML with Monosomy 7 or -5/5q- in Children: A Children’s Oncology Group (COG) Study
• ACNS0333 Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System with Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation 
• ACNS0334 A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy Without Methotrexate
• AEWS0331 European Ewing Tumor Working Initiative of National Groups Ewing Tumor Studies 1999 (EURO-E.W.I.N.G.99)
• ANBL0532 Phase III Randomized Trial of Single vs. Tandem Myeloablative as Consolidation Therapy for High-Risk Neuroblastoma
• ASCT0431 A Randomized Trial of Sirolimus-Based Graft versus Host Disease Prophylaxis after Hematopoietic Stem Cell Transplantation in Relapsed Acute Lymphoblastic Leukemia (ALL)
• PBMTC NMD091 A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children with Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (URTH Trial)
  

Standard Treatment

• Autologous
  • Total Body Irradiation/Etoposide/Cytoxan
  • Fractionated Total Body Irradiation/Cytoxan
  • Carmustine/Etoposide/Ara-C/Cytoxan
  • Carmustine/Ara-C/Etoposide/Melphalan
  • Busulfan/Cytoxan
  • Melphalan/Etoposide/Carboplatinum
  • Melphalan (1)
  • Melphalan (2)
  • Etoposide/Thiotepa/Cytoxan
  • Carboplatin/Thiotepa/Etoposide
    
• Allogeneic
  • Total Body Irradiation/Etoposide/Cytoxan
  • Busulfan/Cytoxan
  • High Dose Cytoxan
  • Fractionated Total Body Irradiation/Cytoxan
  • Single Dose Total Body Irradiation
  • Fludarabine/Busulfan
  • Fludarabine/Cytoxan
  • Fludarabine/Melphalan
  • Fludarabine/Melphalan/ATG (1)
  • Fludarabine/Melphalan/ATG (2)
  • Cytoxan/ATG

Additional Protocols

• 06-0097 Documenting Speech and Language Impairment in Pediatric Oncology Patients with Sensorineural Loss
• ANBL0032 Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
• ASCT0521 Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation.
• ASCT0631 A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source in Matched Sibling Donor Transplantation

Future Protocols

• CIBMTR 06-DON A Multicenter Study of Hematopoietic Stem Cell Donor Safety and Quality of Life
• CTN 0801 A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus plus Prednisone, Sirolimus/Extracorporeal Photopheresis plus Prednisone, and Sirolimus/Calcineurin Inhibitor plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease
• CTN0802 A Multi-Center, Randomized, Double Blind Phase III Trial Evaluating Corticosteroids with Mycophenolate Mofetil vs. Corticosteroids with Placebo as Initial Systemic Treatment of Acute GVHD